Debio 0123 with temozolomide for recurrent or new glioblastoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign consent before any study steps.
- Have glioblastoma that can be seen on a brain MRI with contrast (or have tumor confirmation by biopsy).
- Have enough blood counts and organ function (bone marrow, liver, and kidneys).
- Use effective birth control (or agree to eligible pregnancy-prevention steps).
- Be able to come to scheduled visits and take medicines and tests as planned.
- Prior treatment limits: only 1 (for the GBM line described) and first-line must include TMZ plus radiation for recurrent/progressive cases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a new drug combination for people with newly diagnosed glioblastoma, a type of brain cancer. It adds an immunotherapy drug (adebrelimab) to standard chemotherapy, and some participants also receive hyperbaric oxygen therapy, which may help the treatment work better.
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.